- About the Center
- Research Programs
- Addiction Genetics and Pharmacogenetics Division
- Addiction Treatment and Medication Development Division
- Brain-Behavioral Vulnerabilities Laboratory
- HIV/AIDS Prevention Research Division
- Clinical Trials Network
- Novel Interventions in Criminal Justice Populations Division
- Continuing Care and Assessment Division
- Integrated Care for Primary Care
- Clinical Trial Participation
- Treatment Options
- Affiliated Divisions
- Center Faculty
- Post Doctoral Fellowships
- Public Education and Policy Work
- Contact Us
- Support Our Work
Welcome to the CSA
The primary mission of the CSA is to continue to advance the cutting edge of knowledge on the nature of addiction and the best ways to relieve this terrible illness. Our research is translational in two directions. We carry knowledge from the preclinical laboratory to formal clinical trials in a university setting. We also translate knowledge learned from clinical trials to the average practitioner in the community. Thus the medications and behavioral treatments discovered in our research can have an impact on the care received by patients all over the world.
Developing and maintaining educational programs that teach the causes of addiction and the effective methods used to assess and treat the illness is another key component of our Center’s mission. The design and content of our educational programs strongly reflect the field’s significant research findings, much of which came from studies conducted at the Center. Included in these programs is the University’s full course on addiction, now required for all Penn medical students. Currently, it is the only medical school course of its kind in the United States. We also conduct training of psychiatric residents as well as residents in medicine and primary care. We have an NIH postdoctoral research training program for clinicians desiring board certification in Addiction Psychiatry and for PhDs and MDs desiring a research career in this field.
Essentially, the same research findings that have influenced the design of our educational programs have provided the framework for our Patient Care delivery. The methods we use to diagnose and understand the severity of the illness as well as the interventions for treating it are all part of evidenced-based protocols. Individuals seeking treatment for substance-related addictions may receive care through one of the following options:
- referral to one of the Center’s clinical trials to learn the details of the study and to determine eligibility for enrollment,
- referral to the fee-based, private practice treatment program located at the O’Brien Center, or
- the Center can help the individual arrange a self-referral to one of the local community-based treatment programs.
When option 3 is chosen, the individual should first review the list of community-based programs available (see link below). The Center intake staff will then serve as information resources to help the person select a program that will best match his/her treatment needs.
CSA In the News
Henry R. Kranzler, MD (Professor of Psychiatry and Director of the Center for Studies of Addiction) is examining the genetic risk factors for veterans with chronic use of alcohol, tobacco, and opioids—and all three substances together.
Kyle Kampman, MD received the Dean's Award for Excellence in Clinical Teaching which recognizes clinical teaching excellence and commitment to medical education by outstanding faculty members from affiliated hospitals. Dr. Kampman is the director of the department of psychiatry addiction fellowship at Penn. He also supervises fourth-year medical students during an elective in Addiction Psychiatry.
Dr. Charles O’Brien received the James B. Isaacson Award from the International Society for Biomedical Research on Alcoholism. This honor is the latest in a string of international awards Dr. O’Brien has received for a lifetime of research on the biological basis of alcoholism.
Dr. Kranzler Honored for Addiction Research and Teaching
Henry R. Kranzler, MD, was received the James H. Tharp Award for his work in the area of alcoholism and also received the Dan Anderson Research Award from the Butler Center for Research. The recognized study - Topiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism . Most recently, Dr. Kranzler received the Scott Mackler Award for Excellence in Substance Abuse Teaching.